✦ LIBER ✦

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

✍ Scribed by Gutman, D; Morales, A A; Boise, L H

Book ID: 109886869
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 176 KB
Volume: 23
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2009.123

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High ratio of Duffy (a+b+) phenotype in

High ratio of Duffy (a+b+) phenotype in patients with multiple myeloma compared to healthy controls

✍ Nil Guler; Mehmet Turgut; Duzgun Ozatli; Yasemin Turgut; Ayse Kevser Gokce; Sali 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

The peptide-semicarbazone S-2209, a repr

The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells

✍ Philipp Baumann; Karin Müller; Sonja Mandl-Weber; Johann Leban; Robert Doblhofer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB

IAP family protein expression correlates

IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes

✍ Yasunori Nakagawa; Shinya Abe; Morito Kurata; Maki Hasegawa; Kouhei Yamamoto; Mi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB 👁 2 views

Phase I and II pharmacokinetic and pharm

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

✍ Yoshiaki Ogawa; Kensei Tobinai; Michinori Ogura; Kiyoshi Ando; Takahide Tsuchiya 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

Gene expression profiles associated with

Gene expression profiles associated with MDR1 expression in a doxorubicin-resistant human multiple myeloma cell line

✍ Watts, G.; Futscher, B.; Guzman, M.; Epner, E.; Kunkel, M.; Salmon, S. 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 113 KB

A phase II multiple dose clinical trial

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

✍ Monica Galli; Silvia Salmoiraghi; Joseé Golay; Antonella Gozzini; Claudia Crippa 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 105 KB